Drug Trial Radar · NCT07610213
Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Dec 31, 2029
Study completion Jun 1, 2030
Sponsor
- Lead sponsor
- Abdullah KarsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests a three-phase immune treatment for people recently diagnosed with Type 1 diabetes (within 6 months, with some insulin production remaining). Phase 1 (weeks 1-2): Teplizumab, an anti-CD3 antibody, is given by infusion to slow immune attack on insulin-producing beta cells. Phase 2 (months 2-9): Insulin is injected directly into a lymph node (intralymphatic immunotherapy, ILIT) alongside low-dose interleukin-2 to teach the immune system to tolerate insulin and expand protective regulatory T cells. Phase 3 (months 10-24): Low-dose interleukin-2 is continued to maintain immune tolerance. The main goal is to preserve the body's remaining insulin production (measured by C-peptide). Sixty adults aged 18-45 will be randomly assigned to the MATIN-2 protocol or standard care. Safety, immune markers, and HbA1c will also be monitored.
Conditions
- Type 1 Diabetes Mellitus (T1DM)
- Type 1 Diabetes Mellitus
- Autoimmune Diabetes
Interventions
TeplizumabDrug
Anti-CD3 monoclonal antibody; 14-day IV infusion course at standard dosing (Days 1-14)
Intralymphatic Insulin Immunotherapy (ILIT)Biological
Insulin antigen injected directly into inguinal lymph node; 3 injections at monthly intervals (Months 2-4) combined with low-dose IL-2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Stimulated C-peptide AUCTime frame: Baseline, 6, 12, and 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kara Harp Okulu (Turkish Military Academy)
Ankara, Ankara, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.